You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DPP-4 Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Time in Range Trial in Cairo (Dipeptidyl peptidase-4 inhibitors)

Completed
  • Time in Range
  • Dipeptidyl peptidase-4 inhibitors
  • Cairo, Egypt
    Nancy Elbarbary
Aug 26, 2023

Diabete Type 2 Trial in El Sadat (Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG)

Completed
  • Diabete Type 2
  • Sitagliptin 50 mg
  • +3 more
  • El Sadat, Egypt
    University of Sadat City
Apr 27, 2022

Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,

Recruiting
  • Glucose Metabolism Disorders
  • +3 more
  • Empagliflozin 10 MG
  • Insulin+Metformin+DPP4 inhibitor (DPP4I)
  • Karachi, Pakistan
    SINA Shireen Jinnah colony
Nov 28, 2023

ive Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Active, not recruiting
  • Diabetes
  • Boston, Massachusetts
    Brigham and Women's Hospital
Mar 3, 2023

Harmonizing RCT-Duplicate Emulations In A Real World Replication

Completed
  • Type 2 Diabetes Mellitus
  • Gothenburg, Sweden
    Research Site
Oct 23, 2023

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Boston, Massachusetts
    Bringham Women Hospital
Jan 9, 2023

Healthy Volunteers Trial (gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting), gemigliptin and dapagliflozin

Not yet recruiting
  • Healthy Volunteers
  • gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)
  • gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)
  • (no location specified)
Oct 24, 2021

DPP4 Inhibitor and Coronary Atherosclerosis in Patients

Completed
  • Diabetes Mellitus
  • Bucheon, Korea, Republic of
    Bucheon St. Mary's Hospital
Apr 26, 2021

Type 2 Diabetes Trial in Exeter (Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD)

Completed
  • Type 2 Diabetes
  • Sitagliptin - DPP4i
  • +2 more
  • Exeter, United Kingdom
    Exeter Clinical Research Facility
Mar 30, 2021

Type 2 Diabetes, Inadequate Glucose Control Trial in Busan (duvie)

Completed
  • Type 2 Diabetes Mellitus
  • Inadequate Glucose Control
  • Busan, Korea, Republic of
    Pusan National University Hospital
Jan 4, 2022

Type 2 Diabetes Trial in Dundee (Sulfonylurea, DPP4 Inhibitor)

Completed
  • Type 2 Diabetes
  • Dundee, United Kingdom
    Ninewells Hospital and Medical School
Mar 3, 2021

Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in

Completed
  • Diabetes Mellitus, Type 2
  • Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
  • Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Gentofte, Denmark
  • +12 more
Jan 18, 2022

Diabetes, Stroke Trial in Chiayi City (Metformin plus Pioglitazone plus an SGLT2 inhibitor)

Recruiting
  • Diabetes Mellitus
  • Stroke
  • Metformin plus Pioglitazone plus an SGLT2 inhibitor
  • Chiayi City, Taiwan
    Chang Gung Memorial Hospital, Chiayi Branch
Jan 11, 2022

Diabetes, Type 2 Trial in Kuching (Vildagliptin)

Completed
  • Diabetes Mellitus, Type 2
  • Kuching, Malaysia
    Sarawak General Hospital
Dec 16, 2020

Type2 Diabetes Trial in Copenhagen (Placebo, GIP receptor antagonist, DPP-4 inhibitor)

Completed
  • Type2 Diabetes
  • Placebo
  • +3 more
  • Copenhagen, Hellerup, Denmark
    Center for Clinical Metabolic Research
Mar 15, 2021

Four Second Line Pharmacological Strategies in Type 2 Diabetes

Active, not recruiting
  • Cardiovascular Events
  • +2 more
  • SGLT2 inhibitor
  • +3 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Feb 17, 2022

Diabetes, Type 2 Trial in Korea, Republic of (Pioglitazone + Alogliptin, Alogliptin, Metformin)

Recruiting
  • Diabetes Mellitus, Type 2
  • Pioglitazone + Alogliptin
  • +3 more
  • Bucheon-si, Gyeonggi-do, Korea, Republic of
  • +14 more
Apr 7, 2022

Understand How Oral Semaglutide Works in People With Type 2

Enrolling by invitation
  • Diabetes Mellitus, Type 2
  • Bologna, Italy
  • +17 more
Feb 23, 2023

Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA

Not yet recruiting
  • Cerebral Infarction
  • +2 more
  • Dipeptidyl peptidase-4 inhibitor
  • (no location specified)
Apr 5, 2023

Hyperglycemia, Covid19 Trial in Leòn (Linagliptin tablet, Insulin)

Completed
  • Hyperglycemia
  • Covid19
  • Leòn, Guanajuato, Mexico
    Hospital Regional de Alta Especialidad del Bajìo
Mar 19, 2021

Based on Data From German Sick Funds That Looks at Costs of

Completed
  • Diabetes Mellitus, Type 2
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
Jan 18, 2022

Type 2 Diabetes to Assess Risk of Liver Injury, Kidney Injury,

Completed
  • Diabetes Mellitus, Type 2
  • One Or Multiple Sites, United Kingdom
    RTI health solutions
Aug 2, 2022

Dapagliflozin Versus DPP-4 Inhibitors

Completed
  • Type 2 Diabetes
  • Padova, Italy
    University Hospital of Padova
Mar 9, 2020

Ejection Fraction Trial in Seongnam (Gemigliptin, Glimepiride)

Recruiting
  • Ejection Fraction
  • Seongnam, Gyeonggi, Korea, Republic of
    Seoul National University Bundang Hospital
Dec 22, 2022

NAFLD Trial (sitagliptin and metformin, Sitagliptin, Metformin)

Completed
  • NAFLD
  • sitagliptin and metformin
  • +2 more
  • (no location specified)
Jul 28, 2022